Agendia Presents Data at SABCS 2021 Showing MammaPrint ® and BluePrint ® More Robustly Identify Genomic Differences in HR+ HER2- Breast Cancers in Black and White Women Beyond Clinical Factors
Agendia, Inc., a world leader in precision oncology for breast cancer, today presented data from a research collaboration with Vanderbilt University Medical Center demonstrating the capability of MammaPrint® and BluePrint® to identify differences in recurrence risk and tumor classification amongst different racial groups at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021).
The presentation, titled MammaPrint and BluePrint identify genomic differences in HR+ HER2- breast cancers from young Black and White women, highlights new data signaling that among young women (<50 years of age) with localized hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, MammaPrint and BluePrint identified racial disparities in risk of recurrence and breast cancer subtype distribution not detected by existing clinical factors.
The analysis included 186 Black women and 186 White women under the age of 50 with stage I-III HR+ HER2- breast cancer, matched by age, tumor stage, nodal status and receptor status. Of these patients, Black women were significantly more likely to present as a MammaPrint High Risk 2, and in general had more High Risk tumors compared to White women – who were more likely to have Low Risk tumors, including more MammaPrint UltraLow Risk tumors – despite matching for clinical and pathologic features.
Additionally, the data demonstrated that estrogen-receptor-positive (ER+) tumors reclassified by BluePrint as Basal-type occur at a higher frequency in Black women compared to White women. Basal-type tumors often have worse outcomes compared to ER+, so it is essential to identify this reclassification in Black women to understand the tumor’s biology and ultimately provide better, personalized care. These data underscore the importance of MammaPrint Risk assessment and BluePrint subtyping for providing greater precision in the prediction of risk of recurrence and the selection of therapy.
“It is crucial to identify the genomic differences among young women with breast cancer that may be contributing to racial/ethnic survival disparities, especially given that Black women are more than 40% more likely to die from breast cancer compared to White women,” said Sonya Reid, MD, MPH, Department of Medicine, Vanderbilt University Medical Center. “These data demonstrate the promise of personalized medicine to advance our understanding of racial differences on a genomic level to improve breast cancer outcomes across all racial and ethnic groups.”
Agendia previously presented data at ASCO 2021 which also highlighted the importance of genomic insights that are representative of and effective for diverse patient groups, to better understand and begin to solve for disparities in outcomes.
“Black women continue to remain underrepresented in clinical trials, and this study signifies an important step in measuring the clinical and genomic differences of breast cancers in Black women, which will help to redefine the standard of care and guide treatment planning,” said William Audeh, MD, Chief Medical Officer of Agendia and a study author. “These results provide novel insights about differences in tumor biology; MammaPrint and BluePrint have tremendous potential to add to our understanding of the causes of disparities in survival associated with race, and will help guide therapeutic strategies to improve outcomes. We greatly appreciate the opportunity to collaborate with Dr. Reid and her colleagues at Vanderbilt in this important research.”
Agendia is dedicated to gathering data that has translational potential as well as immediate clinical impact for diverse patient populations. Providing novel insights about tumor biological differences and adding to the body of evidence of genomic profiling of breast cancer based on genetic ancestry is critical to improving patient outcomes. These data underscore the company’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey.
Agendia is a mission-driven company focused on enabling optimized treatment planning by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes and quality of life for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.
MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.
For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Westwicke/ICR Healthcare PR
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vending Machines International Secures SGD 135 Million Capital Commitment From Global Emerging Markets (GEM) as Company Seeks to Go Public26.1.2022 05:02:00 CET | Press release
Vending Machines International (VMI), today announced a SGD 135 Million capital commitment from GEM Global Yield LLC SCS ("GGY"), the Luxembourg-based private alternative investment vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125006251/en/ (Photo: Business Wire) Under the agreement, GGY will provide VMI with a Share Subscription Facility of up to SGD 135 million for a 36-month period following a public listing of VMI’s common stock. VMI will control the timing and maximum amount of drawdowns under this facility and has no minimum drawdown obligation. “VMI is very pleased to be selected by the GEM Group to receive this investment. It is a credit to the GEM management that they very quickly grasped that the world is moving to remove single use plastics from the supply chain. VMI is extremely well placed to take advantage of this transition. With GEM’s funds to strengthen the VMI balance sheet VMI will be able to
Private Messaging App Launches on Quantum Resistant, Decentralized xx network25.1.2022 16:30:00 CET | Press release
The world’s first quantum-resistant messaging app, xx messenger, launched on the xx network today. xx messenger allows users to communicate in real time through hundreds of decentralized nodes operating worldwide. The app is available for download on IOS and Android, features group chat as well as photo and audio sharing, and designed for easy use and switching to from legacy messaging apps. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005773/en/ David Chaum (Photo: Business Wire) Unlike existing messaging apps, xx messenger uses quantum-resistant cryptography to protect message content from decoding and cMix software to obfuscate or shred metadata—information about who sends, when they send, where they send from, and who receives. Randomly selected teams of xx nodes encrypt anonymity sets of 1,000 messages, which are then repeatedly shuffled and have also been encrypted using quantum-resistant cryptography. Informat
MDSLink Makes MaGiC™25.1.2022 16:00:00 CET | Press release
In response to the fiber buildout worldwide, and the continuous demand for reliable bandwidth, MDSLink, Inc. is now offering MaGiC™, a very high-performance, networking module that uses the existing coax. MaGiC is a cost-effective, easy-to-install module that extends the fiber footprint found in MDUs, single-family homes, hotels/resorts and offices or any building with existing coax. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005534/en/ MaGiC Small Form Factor Pluggable (Photo: Business Wire) MaGiC-SFP 2.5™ (Multi-Gigabit Coax Small Form-factor Pluggable) provides up to 2.5 Gbps—symmetrical—actual data rates when plugged into an Ethernet network (SFP/SFP+ port). Applications: - Last 100-meter distribution using existing, in-building coax. - Wireless AP backhaul in-premise. Supplements in-home Wi-Fi® mesh networks using fail safe, wireline backhaul between devices. Using WAPs with SFP-ports, operators can backhaul t
Kroll Unifies Brand to Reflect Strategic Growth and Vision25.1.2022 16:00:00 CET | Press release
Kroll, the leading provider of data, technology and insights related to risk, governance and growth, announces today the completion of its transition to a unified brand. Through its combined capabilities, Kroll is uniquely positioned to help clients stay ahead of complex business demands and opportunities across dynamic regulatory, economic and risk environments. “Our brand unification is a necessary evolution to deliver superior client service and meet and anticipate our clients’ increasingly complex and interconnected needs,” said Jacob Silverman, Chief Executive Officer of Kroll, “This marks the beginning of a new chapter for Kroll that reflects our market leadership across borders and disciplines, and embraces our proprietary data, technology and insights to create value and impact for our clients and communities.” Last year, the Company announced plans to unify its business following significant organic growth and strategic acquisitions. Kroll’s full suite of solutions now span se
Dr. Philip Krause to Provide Strategic Advice to Adjuvance25.1.2022 15:35:00 CET | Press release
Adjuvance Technologies Inc., a privately-held clinical-stage biopharmaceutical company developing next generation saponin adjuvants and vaccines for infectious disease and immuno-oncology, today announced that Philip Krause, MD, will take on a strategic consulting role with the organization as it advances its vaccine development portfolio. Dr. Krause recently served as the Deputy Director, Office of Vaccines Research and Review of the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research. “The deep scientific, regulatory and vaccine development experience that Phil brings to Adjuvance will be instrumental in efficiently developing our shingles vaccine candidate and our pipeline anchored on the next-generation saponin adjuvant TQL-1055,” noted Dr. Tyler Martin, Adjuvance CEO, President and Chairman. “I am thrilled to enhance the company’s expertise with such a well-respected scientist.” Dr. Krause previously had a 30-year career in the FDA where he made majo
Andersen Global Adds Member Firms in Croatia25.1.2022 15:30:00 CET | Press release
Andersen Global continues to cultivate a strong European presence as Croatian tax and advisory firm Andersen BD d.o.o. (formerly BD Savjetovanje d.o.o.) becomes the organization’s newest member firm to adopt the Andersen brand. Andersen Global also welcomes member firm KALLAY & PARTNERS, a Zagreb-based law firm and collaborating firm since 2019. Together, the member firms will provide complementary tax and legal solutions, demonstrating the unified and seamless approach of the global organization. “As tax and legal legislation globally becomes more complex, we aim to continue providing best-in-class service and help our clients navigate the various aspects of their business operations,” said Branka Topolovec new Managing Partner of Andersen in Croatia. “The adoption of the Andersen brand is a milestone for our firm’s growth and development and gives us a competitive advantage in the market by allowing us to provide our clients with a full suite of capabilities in Croatia as well as glo
UVD Robots Joins Ecolab’s Global Infection Prevention Offerings to Fight Hospital Acquired Infections25.1.2022 15:02:00 CET | Press release
As new coronavirus variants spread, the growth in demand for infection prevention solutions using UV-C light is projected to reach $18.94 billion by 2030, witnessing an annual growth rate of 59.7% from 2021 to 2030. Further fueling the demand is the rise in hospital acquired infections (HAIs) globally causing more fatalities due to the increase in antibiotic resistance from even simple infections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005148/en/ Disinfecting hospitals with UV-C lights is not a new concept, however, existing solutions including UV ceiling lights, stationary cleaning robots, and air purifiers may not reach shadowed or remote areas as well as the mobile platform offered by the autonomous UVD Robots. (Photo: Business Wire) Autonomous UV-C disinfection robots have emerged as a solution to supplement standard cleaning and disinfection practices to address HAIs and heightened hygiene requirements due